236 related articles for article (PubMed ID: 7964961)
21. Does dexamethasone enhance the efficacy of alizapride in cis-platinum-induced delayed vomiting and nausea?
Münstedt K; Wunderlich I; Blauth-Eckmeyer E; Zygmunt M; Vahrson H
Oncology; 1998; 55(4):293-9. PubMed ID: 9663418
[TBL] [Abstract][Full Text] [Related]
22. Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy.
Benoit Y; Hulstaert F; Vermylen C; Sariban E; Hoyoux C; Uyttebroeck A; Otten J; Laureys G; De Kerpel I; Nortier D
Anticancer Drugs; 1995 Feb; 6 Suppl 1():9-14. PubMed ID: 7749170
[TBL] [Abstract][Full Text] [Related]
23. Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
Nicolaides C; Giannakakis T; Skarlos D; Athanassiadis A; Fountzilas G; Damigos D; Pavlidis N
J Exp Clin Cancer Res; 1998 Mar; 17(1):71-5. PubMed ID: 9646236
[TBL] [Abstract][Full Text] [Related]
24. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea.
Drechsler S; Bruntsch U; Eggert J; Grote-Kiehn J; Gosse H; Bangerter M; Ukena D; Oehm C; Mezger J; Faerber L; Imhoff W; Untch M; Gallmeier WM
Support Care Cancer; 1997 Sep; 5(5):387-95. PubMed ID: 9322351
[TBL] [Abstract][Full Text] [Related]
25. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
[TBL] [Abstract][Full Text] [Related]
26. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients.
Uysal KM; Olgun N; Sarialioğlu F
Turk J Pediatr; 1999; 41(2):207-18. PubMed ID: 10770660
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
28. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
Barbounis V; Koumakis G; Hatzichristou H; Vassilomanolakis M; Tsoussis S; Efremidis A
Support Care Cancer; 1999 Mar; 7(2):79-83. PubMed ID: 10089087
[TBL] [Abstract][Full Text] [Related]
29. Study of efficacy and tolerability of tropisetron in the prevention of cisplatin induced nausea and vomiting.
Chiersilpa A; Ngow J
J Med Assoc Thai; 1999 Sep; 82(9):915-21. PubMed ID: 10561949
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Malik I; Moid I; Khan Z; Hussain M
Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.
Herrstedt J; Sigsgaard TC; Nielsen HA; Handberg J; Langer SW; Ottesen S; Dombernowsky P
Support Care Cancer; 2007 Apr; 15(4):417-26. PubMed ID: 17093916
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
33. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
34. Tropisetron (Navoban) compared with alizapride in the control of emesis induced by cyclophosphamide-containing regimens.
De Nigris A; Paladini G; Giosa F; Sfeir C; Pagan MG; Maltoni C
Eur J Cancer; 1994; 30A(12):1902-3. PubMed ID: 7880624
[No Abstract] [Full Text] [Related]
35. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
36. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Otten J; Hachimi-Idrissi S; Balduck N; Maurus R
Semin Oncol; 1994 Oct; 21(5 Suppl 9):17-9. PubMed ID: 9113122
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
40. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
